2025 Q1 M&A and Strategic Collaborations
- April 7, 2025
Please complete the form below to download Oppenheimer's Biopharma 2025 Q1 M&A Strategic Collaboration Insights
Michael A. Margolis, R.Ph.
Title:Senior Managing Director, Head of Healthcare Investment Banking
Daniel Parisotto, PhD
Title:Managing Director, Healthcare Investment Banking
DISCLOSURES
This notice is provided for informational purposes only, and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
2025 Oppenheimer & Co. Inc. Transacts Business on all Principal Exchanges and Member SIPC 7824953.1